In the above-named article by Smith TJ (J Clin Endo Metab. 2022; 107:s13-s26; doi: 10.1210/clinem/dgac328), two errors appeared in the published paper:
In the section “K1-70, A Monoclonal TSHR Blocking Antibody,” the sentence ”Two patients experienced clinically meaningful reductions” should read as “As many as 5 patients experienced clinically meaningful reductions.”
In Figures 3 and 4 and in the legends to Figures 3 and 4, “VRDRL” should read as “VRDN-001”
The errors have been corrected online.